OBJECTIVE: The loudness dependence of the auditory evoked potential (LDAEP) has been known as an indicator of central serotonergic neurotransmission. Nicotine increases the release of serotonin levels. The current study investigated whether cigarette smoking would make difference in LDAEP among male patients with major depressive disorder. METHODS: Twenty-four non-smoking and 20 smoking male patients meeting DSM-IV criteria for major depressive disorder (MDD) were recruited. There was no significant difference in severity of MDD symptoms between the two groups. The age of participants ranged from 20 to 65 years old. Event-related potentials (ERP) N100 were measured on 5 different sounds (55, 65, 75, 85, 95 dB) and on 5 electrodes (Fz, Cz, Pz, C5, C6). The N1/P2 peak to peak amplitudes and amplitude slope according to 5 different sounds were calculated. RESULTS: LDAEP was significantly weaker in the smoking group in comparison to the non-smoking group (p<0.05). Among non-smoking group LDAEP was negatively correlated with a core depression subscale of Hamilton Rating Scale for Depression (HAM-D) (r=-0.41, p<0.05). CONCLUSION: LDAEP of the smoking patients with MDD group was weaker than the non-smoking patient with MDD group's. This result suggests that smoking may have increased the release of serotonergic neurotransmission in patients with MDD. Future studies need to examine LDAEP changes before and after tobacco use among smoking patients.
Depression ; Depressive Disorder, Major ; Diagnostic and Statistical Manual of Mental Disorders ; Electrodes ; Evoked Potentials ; Evoked Potentials, Auditory ; Humans ; Male ; Nicotine ; Serotonin ; Smoke ; Smoking ; Synaptic Transmission ; Tobacco

OBJECTIVES: N100 amplitude slope(the intensity dependence of the cortical auditory evoked potentials) is widely considered as an indirect indicator of central serotonergic neurotransmission. However, there are only a few studies about N100 amplitude slopes of major psychiatric disorders. In this study, we examined N100 amplitude slope differences among major depressive disorder(MDD), bipolar disorder(BD), schizophrenia (SCZ) and normal controls(NC). METHODS: We measured the N100 amplitude slopes of 35 patients with MDD, 33 patients with BD, 27 patients with SCZ and 35 NC subjects. Amplitude differences from N1 to P2 at the five different sound intensities(55, 65, 75, 85 and 95dB) were examined at Cz electrode. The N100 amplitude slope was calculated as the linear regression of five N1/P2 peak-to-peak amplitudes across stimulus intensities. RESULTS: BD patients showed significantly reduced N100 amplitude slope compared with NC(0.54+/-0.70 vs. 0.96+/-0.72, p=0.035). N100 amplitude slope of SCZ patients was significantly reduced compared with NC(0.50 +/-0.47 vs. 0.96+/-0.72, p=0.027). N100 amplitude slope of BD patients was significantly lower than that of MDD patients(0.54+/-0.70 vs. 0.94+/-0.60, p=0.046). SCZ patients also showed significant reduction of N100 amplitude slope compared with MDD patients(0.50+/-0.47 vs. 0.94+/-0.60, p=0.036). There was no significant difference of N100 amplitude slope between MDD patients and NC(0.94+/-0.60 vs. 0.96+/-0.72, p=1.000). CONCLUSION: Interestingly, the N100 amplitude slopes of BD and SCZ were reduced compared to NC and MDD patients. Our results suggest the predictive use of N100 amplitude slope in making differential diagnoses of major psychiatric disorders. Clinical implications of N100 amplitude slope in major psychiatric disorders were discussed.
Bipolar Disorder ; Depressive Disorder, Major ; Diagnosis, Differential ; Electrodes ; Humans ; Linear Models ; Schizophrenia ; Synaptic Transmission

A new staging system for multiple myeloma (MM) has utilized serum concentrations of beta 2-microglobulin (S beta2 M) and albumin as important prognostic factors for survival. Since S beta2 M is an indicator of glomerular filtration rate, we compared the prognostic values of S beta2 M and 24-hr urinary creatinine clearance (Ccr) in patients with MM. We retrospectively reviewed the records of 170 MM patients from January 1996 to November 2003 whose 24-hr urinary Ccr was available at the time of diagnosis. We found that pretreatment S beta2 M was inversely related to Ccr (Spearman's correlation coefficient=-0.787). In univariate analysis, the hazard ratio (HR) of death was 1.043 (p<0.001) for S beta2 M and 0.985 (p<0.001) for Ccr. Multivariate analysis showed that S beta2 M (HR 1.030, p=0.010) and Ccr (HR 0.993, p=0.059) were significant prognostic factors in patients' survival. In conclusion, 24-hr urinary Ccr may be utilized for staging of patients with MM.
beta 2-Microglobulin/*blood ; Survival Analysis ; Retrospective Studies ; Prognosis ; Neoplasm Staging/methods ; Multivariate Analysis ; Multiple Myeloma/drug therapy/metabolism/*pathology ; Creatinine/*urine

No abstract available.
Aged ; Bone Marrow/pathology ; Genome, Human ; Humans ; Isochromosomes/*genetics ; Karyotyping ; Leukemia, Myeloid, Acute/complications/*diagnosis/genetics ; *Loss of Heterozygosity ; Male ; Oligonucleotide Array Sequence Analysis ; Thrombocytosis/*etiology

BACKGROUND: Acute promyelocytic leukemia (APL) can be life threatening, necessitating emergency therapy with prompt diagnosis by morphologic findings, immunophenotyping, cytogenetic analysis, or molecular studies. This study aimed to assess the current routine practices in APL and the clinico-pathologic features of APL. METHODS: We reviewed the medical records of 48 Korean patients (25 men, 23 women; median age, 51 (20-80) years) diagnosed with APL in 5 university hospitals between March 2007 and February 2012. RESULTS: The WBC count at diagnosis and platelet count varied from 0.4 to 81.0 (median 2.0)x10(9)/L and 2.7 to 124.0 (median 54.5)x10(9)/L, respectively. The median values for prothrombin time and activated partial thromboplastin time were 14.7 (11.3-44.1) s and 29 (24-62) s, respectively. All but 2 patients (96%) showed a fibrin/fibrinogen degradation product value of >20 microg/mL. The D-dimer median value was 5,000 (686-55,630) ng/mL. The t(15;17)(q22;q12 and PML-RARA fusion was found in all patients by chromosome analysis and/or multiplex reverse transcriptase-polymerase chain reaction (RT-PCR), with turnaround times of 8 (2-19) d and 7 (2-13) d, respectively. All patients received induction chemotherapy: all-trans retinoic acid (ATRA) alone (N=11, 26%), ATRA+idarubicin (N=25, 58%), ATRA+cytarabine (N=3, 7%), ATRA+idarubicin+cytarabine (N=4, 9%). CONCLUSION: Since APL is a medical emergency and an accurate diagnosis is a prerequisite for prompt treatment, laboratory support to implement faster diagnostic tools to confirm the presence of PML-RARA is required.
Cytogenetic Analysis ; Emergencies ; Emergency Treatment ; Fibrin Fibrinogen Degradation Products ; Hospitals, University ; Humans ; Immunophenotyping ; Korea ; Leukemia, Promyelocytic, Acute ; Male ; Medical Records ; Partial Thromboplastin Time ; Platelet Count ; Prothrombin Time ; Tretinoin

BACKGROUND: Acute promyelocytic leukemia (APL) can be life threatening, necessitating emergency therapy with prompt diagnosis by morphologic findings, immunophenotyping, cytogenetic analysis, or molecular studies. This study aimed to assess the current routine practices in APL and the clinico-pathologic features of APL. METHODS: We reviewed the medical records of 48 Korean patients (25 men, 23 women; median age, 51 (20-80) years) diagnosed with APL in 5 university hospitals between March 2007 and February 2012. RESULTS: The WBC count at diagnosis and platelet count varied from 0.4 to 81.0 (median 2.0)x10(9)/L and 2.7 to 124.0 (median 54.5)x10(9)/L, respectively. The median values for prothrombin time and activated partial thromboplastin time were 14.7 (11.3-44.1) s and 29 (24-62) s, respectively. All but 2 patients (96%) showed a fibrin/fibrinogen degradation product value of >20 microg/mL. The D-dimer median value was 5,000 (686-55,630) ng/mL. The t(15;17)(q22;q12 and PML-RARA fusion was found in all patients by chromosome analysis and/or multiplex reverse transcriptase-polymerase chain reaction (RT-PCR), with turnaround times of 8 (2-19) d and 7 (2-13) d, respectively. All patients received induction chemotherapy: all-trans retinoic acid (ATRA) alone (N=11, 26%), ATRA+idarubicin (N=25, 58%), ATRA+cytarabine (N=3, 7%), ATRA+idarubicin+cytarabine (N=4, 9%). CONCLUSION: Since APL is a medical emergency and an accurate diagnosis is a prerequisite for prompt treatment, laboratory support to implement faster diagnostic tools to confirm the presence of PML-RARA is required.
Cytogenetic Analysis ; Emergencies ; Emergency Treatment ; Fibrin Fibrinogen Degradation Products ; Hospitals, University ; Humans ; Immunophenotyping ; Korea ; Leukemia, Promyelocytic, Acute ; Male ; Medical Records ; Partial Thromboplastin Time ; Platelet Count ; Prothrombin Time ; Tretinoin